William Blair Has Optimistic Outlook of Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Equities researchers at William Blair lifted their Q2 2025 earnings per share (EPS) estimates for shares of Hologic in a report issued on Monday, November 11th. William Blair analyst A. Brackmann now expects that the medical equipment provider will earn $1.07 per share for the quarter, up from their prior forecast of $1.05. The consensus estimate for Hologic's current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic's Q3 2025 earnings at $1.10 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same quarter last year, the company posted $0.89 earnings per share. The company's quarterly revenue was up 4.5% compared to the same quarter last year.

HOLX has been the topic of a number of other reports. UBS Group raised their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Evercore ISI upped their target price on Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. StockNews.com raised Hologic from a "hold" rating to a "buy" rating in a report on Thursday. Finally, Citigroup downgraded Hologic from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $89.91.

Hologic Stock Performance

HOLX traded down $1.64 during trading hours on Thursday, hitting $77.54. 1,648,462 shares of the stock were exchanged, compared to its average volume of 1,592,817. The stock has a market cap of $18.01 billion, a price-to-earnings ratio of 23.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98. The stock has a 50-day simple moving average of $80.84 and a 200-day simple moving average of $78.22. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a 12 month low of $67.59 and a 12 month high of $84.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wolff Wiese Magana LLC bought a new position in Hologic during the 3rd quarter valued at $25,000. Innealta Capital LLC acquired a new stake in shares of Hologic in the second quarter worth $25,000. iA Global Asset Management Inc. bought a new position in Hologic in the 1st quarter worth $37,000. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Finally, Sunbelt Securities Inc. bought a new stake in Hologic during the second quarter valued at about $37,000. 94.73% of the stock is currently owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.